Valuation
- Market cap
- 7,000
- Revenue TTM
- $25,770,000
- Net income TTM
- $-56,030,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -217.42%
- Debt to equity
- -0.86
Trading
- Volume
- 39,100
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 73,340,000
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-...
Show more
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 456 4718
- Website
- https://www.gelesis.com
- Address
- 501 Boylston Street, Suite 6102, Boston, United States
Latest news
No headlines yet.
